SCHEMBL352833

SCHEMBL352833

Cc1onc(CO)c1C(=O)N(C)Cc1csc(NC(=O)NCc2cccc(F)c2)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 12/20 0.49
ROCK1 Q13464 12/20 0.49
ATG4B Q9Y4P1 1/20 0.41
SCD5 Q86SK9 1/20 0.39
EPHX2 P34913 1/20 0.38
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
HSD17B10 Q99714 2/20 0.38
GAA P10253 1/20 0.38
TSHR P16473 1/20 0.38
SGK1 O00141 1/20 0.37
AKT1 P31749 1/20 0.37
GSK3B P49841 1/20 0.37
LIMK1 P53667 1/20 0.37
TNK2 Q07912 1/20 0.37
DMPK Q09013 1/20 0.37
MYLK Q15746 1/20 0.37
CDC42BPA Q5VT25 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL353432 0.94 ROCK2 (0.49) ROCK2ROCK1ATG4BSCD5EPHX2
SCHEMBL355123 0.91 ROCK2 (0.51) ROCK2ROCK1ATG4BSCD5EPHX2
SCHEMBL4725993 0.89 ROCK1 (0.47) ROCK2ROCK1ATG4BSCD5EPHX2
SCHEMBL351593 0.89 ROCK2 (0.49) ROCK2ROCK1ATG4BSCD5EPHX2
SCHEMBL4777272 0.87 ROCK2 (0.50) ROCK2ROCK1ATG4BEPHX2SGK1
SCHEMBL19118745 0.87 ROCK1 (0.47) ROCK2ROCK1ATG4BSCD5EPHX2
Hydrochloric Acid SCHEMBL4725212 0.87 ROCK2 (0.49) ROCK2ROCK1ATG4BEPHX2SGK1
SCHEMBL354004 0.86 HTT (0.49) ROCK2ROCK1ATG4BSCD5KMT2A
SCHEMBL353559 0.85 ROCK2 (0.52) ROCK2ROCK1ATG4BSCD5EPHX2
SCHEMBL354050 0.84 ROCK1 (0.54) ROCK2ROCK1ATG4BEPHX2SGK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2200440-B1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS CRESTONE INC (US) 2017-07-19 EP claimed
US-8148380-B2 Antibacterial amide and sulfonamide substituted heterocyclic urea compounds CRESTONE, INC. (US) 2012-04-03 US claimed
US-20120015941-A1 Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds CRESTONE, INC. (US) 2012-01-19 US claimed
EP-2200440-A1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS Crestone, Inc. (US) 2010-06-30 EP claimed
WO-2009015208-A1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS REPLIDYNE, INC. (US) 2009-01-29 WO claimed
EP-2200440-B1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS CRESTONE INC (US) 2017-07-19 EP disclosed
US-8148380-B2 Antibacterial amide and sulfonamide substituted heterocyclic urea compounds CRESTONE, INC. (US) 2012-04-03 US disclosed
US-20120015941-A1 Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds CRESTONE, INC. (US) 2012-01-19 US disclosed
EP-2200440-A1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS Crestone, Inc. (US) 2010-06-30 EP disclosed
WO-2009015208-A1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS REPLIDYNE, INC. (US) 2009-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015941-A1 Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds NAAA, AADAC, RPSA ROCK2 4626/4885ROCK1 4747/4885ATG4B 761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.